CD8A and cancer: We also found that combined administration of TEM and anti-PD-L1 increased the number and activity of CD8+ T cells and this is consistent with a recent report that mTOR inhibition and combination therapy with an immune checkpoint inhibitor can enhance the anti-cancer effect [24,44].